MAPT and Alzheimer disease: Based on biomarker studies of AD, by the time cognitive decline becomes detectable, neuropathological changes of AD have already occurred, first in Aß and subsequently in tau-related measures8 and therefore cannot be used to select patients for early disease stage studies.